Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 3/20 | 0.62 |
| ▸ | CDK2 | P24941 | 3/20 | 0.62 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | CA12 | O43570 | 14/20 | 0.51 |
| ▸ | CA1 | P00915 | 14/20 | 0.51 |
| ▸ | CA2 | P00918 | 14/20 | 0.51 |
| ▸ | CA9 | Q16790 | 14/20 | 0.51 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6286722 | 0.85 | CCNE1 (0.68) | CCNE1CDK2CDK5KMT2ACA12 | |
| SCHEMBL6286065 | 0.83 | CCNE1 (0.70) | CCNE1CDK2CDK5KMT2AMEN1 | |
| SCHEMBL6282353 | 0.82 | CCNE1 (0.68) | CCNE1CDK2CDK5KMT2AMEN1 | |
| SCHEMBL6281751 | 0.82 | CDK2 (0.90) | CCNE1CDK2CDK5KMT2AMEN1 | |
| SCHEMBL6282741 | 0.81 | CA12 (0.61) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL6287998 | 0.81 | CCNE1 (0.70) | CCNE1CDK2CDK5KMT2AMEN1 | |
| SCHEMBL6283947 | 0.81 | CCNE1 (0.62) | CCNE1CDK2CDK5KMT2AMEN1 | |
| SCHEMBL6288092 | 0.79 | CCNE1 (0.64) | CCNE1CDK2CDK5KMT2AMEN1 | |
| SCHEMBL6285521 | 0.78 | CDK2 (0.69) | CCNE1CDK2CDK5KMT2ACA12 | |
| SCHEMBL6278409 | 0.77 | CNR1 (0.70) | CCNE1CDK2CDK5KMT2ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157827-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PEVARELLO PAOLO (IT) | 2004-08-12 | — | — | US | claimed |
| US-20030187040-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN SPA (IT) | 2003-10-02 | — | — | US | claimed |
| US-6863647-B2 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN S.P.A. (IT) | 2005-03-08 | — | — | US | disclosed |
| US-20040157827-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PEVARELLO PAOLO (IT) | 2004-08-12 | — | — | US | disclosed |
| US-20030187040-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN SPA (IT) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187040-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | UCK2, ULK3, CDK2 | CCNE1 83/4885CDK2 3/4885CDK5 129/4885 |
| US-20040157827-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | UCK2, ULK3, CDK2 | CCNE1 83/4885CDK2 3/4885CDK5 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.